Costs of Treatment in Patients With Moderate to Severe Plaque Psoriasis

Authors:
  • VHVera M. R. Heydendael
    Vera M. R. Heydendael
  • CBCorianne A. J. M. de Borgie
    Corianne A. J. M. de Borgie
  • PSPhyllis I. Spuls
    Phyllis I. Spuls
  • PBPatrick M. M. Bossuyt
    Patrick M. M. Bossuyt
  • JBJan D. Bos
    Jan D. Bos
  • MRMenno A. de Rie
    Menno A. de Rie

Abstract
PSORIASIS IS a chronic disease for which only remissive, as opposed to curative, treatments are currently available. Methotrexate and cyclosporine are now the predominant systemic treatment modalities for patients with moderate to severe psoriasis. They have been used as such for the past 40 and 20 years, respectively. Therapy with methotrexate has been evaluated in noncomparative trials, reporting effective induction and maintenance of remission in patients with severe psoriasis.1 In addition, there is strong evidence supporting the use of cyclosporine, and optimal dosage and treatment schemes for cyclosporine have been systematically assessed.2

This publication has 10 references indexed in Scilit: